| 李 峰,王 布,徐凯伦,武伟泽,张志华,赵建清.非小细胞肺癌组织NEK2、EPHA5表达与临床病理特征、EGFR突变和预后的关系[J].,2024,(12):2396-2400 |
| 非小细胞肺癌组织NEK2、EPHA5表达与临床病理特征、EGFR突变和预后的关系 |
| Relationship between the Expression of NEK2, EPHA5 and Clinicopathological Features, EGFR Mutation and Prognosis in Non-Small Cell Lung Cancer Tissues |
| 投稿时间：2024-02-21 修订日期：2024-03-18 |
| DOI：10.13241/j.cnki.pmb.2024.12.039 |
| 中文关键词: 非小细胞肺癌 NEK2 EPHA5 临床病理特征 EGFR突变 预后 |
| 英文关键词: Non-small cell lung cancer NEK2 EPHA5 Clinicopathological features EGFR mutation Prognosis |
| 基金项目:河北省科技计划项目（20377717D） |
|
| 摘要点击次数: 178 |
| 全文下载次数: 137 |
| 中文摘要: |
| 摘要 目的：探讨非小细胞肺癌（NSCLC）组织有丝分裂相关激酶2（NEK2）、促红细胞生成素产生肝细胞受体A5（EPHA5）表达情况，分析其与临床病理特征、表皮生长因子受体（EGFR）突变和预后的关系。方法：选取自2019年10月至2020年10月期间我院诊治的151例NSCLC患者作为研究对象，术中取其癌组织及癌旁正常组织（距离癌组织5cm以上）。采用实时荧光定量聚合酶链式反应（RT-PCR）检测EGFR基因表达。免疫组织化学法检测癌组织和癌旁组织中NEK2、EPHA5表达。比较癌组织和癌旁组织NEK2、EPHA5表达情况。分析不同临床病理特征NSCLC患者NEK2、EPHA5表达情况。分析EGFR突变型与野生型不同NEK2、EPHA5表达情况。Kaplan-Meier生存曲线分析不同NEK2、EPHA5表达对NSCLC患者的预后情况。结果：与癌旁组织比较，癌组织NEK2、EPHA5阳性表达率明显更高（均P＜0.05）；与TNM分期Ⅰ～Ⅱ期、无淋巴结转移和肿瘤直径＜5 cm患者相比，TNM分期ⅢA期、淋巴结转移和肿瘤直径≥5 cm患者的NEK2、EPHA5阳性表达率均明显更高（均P＜0.05）；EGFR突变型组NEK2、EPHA5阳性表达率显著高于EGFR野生型组（均P＜0.05）；NEK2阳性表达组和阴性表达组3年总生存率（OS）分别为40.40%（40/99），57.69%（30/52），EPHA5阳性表达组和阴性表达组患者3年OS分别为41.90%（44/105），56.52%（26/46），各阴性表达组患者累积生存显著高于阳性表达组（P＜0.05）。结论：NSCLC癌组织中NEK2、EPHA5阳性表达率升高，与TNM分期ⅢA期、淋巴细胞转移、肿瘤直径有关，还可能导致EGFR突变和不良预后。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression of mitosis-associated kinase 2 (NEK2) and erythropoietin-producing hepatocyte receptor A5 (EPHA5) in non-small cell lung cancer (NSCLC) tissues, and to analyze their relationship with clinicopathological features, epidermal growth factor receptor (EGFR) mutation and prognosis. Methods: 151 NSCLC patients who were diagnosed and treated in our hospital from October 2019 to October 2020 were selected as research objects, the cancer tissues and adjacent normal tissues (more than 5cm from the cancer tissues) were taken during the operation. The expression of EGFR gene was detected by real-time fluorescence quantitative polymerase chain reaction (RT-PCR). The expression of NEK2 and EPHA5 in cancer tissues and adjacent tissues was detected by immunohistochemistry. The expression of NEK2 and EPHA5 in cancer tissues and adjacent tissues was compared. The expression of NEK2 and EPHA5 in NSCLC patients with different clinicopathological features was analyzed. The expression of NEK2 and EPHA5 in different EGFR mutant and wild type was analyzed. The prognosis of NSCLC patients with different NEK2 and EPHA5 expression were analyzed by Kaplan-Meier survival curve. Results: Compared with adjacent tissues, the positive expression rates of NEK2 and EPHA5 in cancer tissues were significantly higher (all P<0.05). The positive expression rates of NEK2 and EPHA5 in patients with TNM stage IIIA, lymph node metastasis and tumor diameter≥5 cm were significantly higher than those in patients with TNM stage I～II, no lymph node metastasis and tumor diameter<5 cm(all P<0.05). The positive expression rates of NEK2 and EPHA5 in EGFR mutant group were significantly higher than those in EGFR wild type group (all P<0.05). The 3-year overall survival rate (OS) in NEK2 positive expression group and negative expression group were 40.40% (40/99) and 57.69% (30/52) respectively. The 3-year OS in EPHA5 positive expression group and negative expression group were 41.90% (44/105) and 56.52% (26/46) respectively, the cumulative survival of patients in each negative expression group were significantly higher than those in positive expression group (P<0.05). Conclusion: The positive expression rates of NEK2 and EPHA5 in NSCLC cancer tissues are increase, which are relate to TNM stage IIIA, lymph node metastasis, tumor diameter, and may also lead to EGFR mutation and poor prognosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
